Business Wire

DE-CSC

3.9.2024 15:01:35 CEST | Business Wire | Press release

Share
Project Finance Use to Surge Over the Next Two Years

An overwhelming majority (86%) of industry experts believe project finance as a method of financing large scale infrastructure projects will grow in use over the next two years. This is according to a major new global study1 commissioned by CSC, the world’s leading provider of global business administration and compliance solutions.

North America, benefitting from the Inflation Reduction Act (IRA) among other tailwinds, is predicted to see the most significant uptick in project finance activity over the next two years, selected by over a third (39%) of respondents.

On a sectoral level, renewable energy projects such as wind and solar are seeing the most activity, representing the primary focus area for over half (55%) of respondents. This is followed by infrastructure, including roads, bridges and airports (29%). Within renewables, solar is expected to see the biggest increase in deals over the next 24 months.

CSC’s Project Finance Report 2024 focuses on the outlook for project finance deal activity across regions and sectors globally. The findings are based on the views of industry professionals working in project finance across North America, Europe, the U.K., Latin America, and Asia Pacific (APAC), in industries including banking and finance, development and construction, power and energy.

Corresponding with these findings, CSC has anecdotally observed a recent increase in project finance related deal flow.

“We're seeing renewed momentum for project finance deals across various markets as pandemic-related obstacles recede and supportive regulatory changes and legislation take root,” says Bryan Gartenberg, managing director at CSC. “Growing urgency to invest in renewable energy infrastructure coupled with global demographic shifts and rising prosperity are all driving demand for project finance, giving rise to new opportunities and challenges for market participants.”

Regional growth

While deal growth is expected in all surveyed regions, North America is predicted to be the most dynamic. This is, in part, due to the IRA, though Export Credit Agencies (ECAs) are also seen as being central to driving sponsorship of project finance structures and attracting institutional investors.

North America is followed by Latin America, Europe—which is enjoying supportive regulation in the form of European Long-Term Investment Funds (ELTIF 2.0)—and the U.K., with 29% of those surveyed expecting each of these regions to see an increase in activity.

In line with the report’s findings, CSC has observed conditions for growth in the Latin American market.

“While Latin America is slightly behind globally when it comes to the investment in the infrastructure and energy sectors, investment in the sector is a key objective for many of the regions’ administrations, and will fuel economic and GDP growth,” says Michael Morcom, managing director, Latin America at CSC. “Countries such as Brazil have introduced new regulations for infrastructure debentures and have allowed power purchase agreements (PPAs) to be denominated in U.S. dollars with the goal of attracting more foreign investment, and we’re seeing stirrings in other markets such as Colombia, Argentina, and Peru, following a few years of under-investment.”

APAC, meanwhile, was cited by just over a quarter (26%) of those surveyed.

“APAC is increasingly active in project financing, particularly in Australia where there is a strong commitment to net zero, and in Japan, which is exporting capital through its large banks to projects in the APAC region,” says Con Kleanthous, managing director, APAC at CSC.

Sector growth

The top four industries respondents are currently focused on are renewable energy projects (cited by 55% of respondents); infrastructure (29%); oil and gas (25%); and real estate development (24%).

Within the renewable energy project space, respondents believe solar will see the biggest increase in deals over the next two years, followed by wind (24%), fuel cell (14%), and green hydrogen (12%).

“Wind and solar are at the forefront because of their proven track record on bankability, but as emerging technologies are proven to be successful from a financing perspective, we can expect to see more growth in newer asset classes like hydrogen. This is, in turn, engendering ever-complex project finance structures needed to accommodate them,” says Gartenberg.

“As these structures grow in complexity, it’s increasingly important to ensure that all parties involved have the right levels of experience and knowledge—particularly when a project goes across multiple countries and local financial and regulatory expertise is needed,” continues Gartenberg. “Engaging a trust and agency service provider with a robust understanding of local markets, a strong track record, and the ability to take on various roles—including that of collateral agent, account bank, administrative agent, and inter-creditor agent—can thus play a key role in minimizing risks and ensuring that a deal runs smoothly and protects stakeholders’ interests.”

To receive a copy of CSC’s Project Finance Report 2024 report, please contact Camilla Wyatt or Lucy Gibbs at cscteam@citigatedewerogerson.com.

Notes to editors

1 CSC, in partnership with Pure Profile, surveyed 200 industry professionals working in project finance to understand their views on which regions are currently seeing the greatest activity for project finance deals, and how this will change in the near future. Respondents were split across North America, Europe, the UK, Latin America, and Asia Pacific, and worked across different industries, including banking and finance, construction, and energy.

About CSC

CSC is the trusted partner of choice for more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands (Interbrand®), and more than 70% of the PEI 300. We are the world’s leading provider of global business administration and compliance solutions, specialized administration services to alternative asset managers across a range of fund strategies, transactions involving capital markets participants in both public and private markets, domain name system management and digital brand and fraud protection, and corporate tax software solutions. Founded in 1899 and headquartered in Wilmington, Delaware, USA, CSC prides itself on being privately held and professionally managed for more than 125 years. CSC has office locations and capabilities in more than 140 jurisdictions across Europe, the Americas, Asia Pacific, and the Middle East. We are a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. We are the business behind business®. Learn more at cscglobal.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903259861/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye